Imbalances in posttranslational modification of SR proteins in cells harboring SRPK1 mutants not only affect splicing efficiency and alternative splicing but is also a disease phenotype in certain cancers and therefore the inhibition of SRPK1 is a drug target (1, 2). Here, SRPK1 is linked to cancer.